BAYRY
Bayer AG (ADR)

2,773
Mkt Cap
$43.66B
Volume
1.26M
52W High
$14.85
52W Low
$6.97
PE Ratio
-17.52
BAYRY Fundamentals
Price
$11.11
Prev Close
$11.28
Open
$11.23
50D MA
$11.27
Beta
0.47
Avg. Volume
1.48M
EPS (Annual)
-$1.04
P/B
1.31
Rev/Employee
$583,970.35
$77,587.35
Loading...
Loading...
News
all
press releases
BAYRY's Kerendia Label Expansion Application Gets Priority Review
Bayer wins FDA Priority Review for Kerendia label expansion in CKD tied to type I diabetes after strong phase III data.
News Placeholder
More News
News Placeholder
BAYRY or RHHBY: Which Is the Better Value Stock Right Now?
BAYRY vs. RHHBY: Which Stock Is the Better Value Option?
News Placeholder
Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B
REGN teams up with Parabilis in a potential $2.2B deal to develop Antibody-Helicon Conjugates targeting hard-to-treat cancers.
News Placeholder
FDA Grants Priority Tag to Bayer's Oncology Drug for First-Line NSCLC
BAYRY wins FDA priority review for sevabertinib in first-line HER2-mutant NSCLC, building momentum for the oral TKI.
News Placeholder
Bayer Gets FDA Priority Review for Asundexian NDA in Stroke Prevention
BAYRY gains FDA Priority Review for asundexian NDA after phase III data showed a 26% cut in ischemic stroke risk without more major bleeding.
News Placeholder
Bayer Q1 Earnings Beat Estimates, Crop Science Unit Boosts Sales
BAYRY beats Q1 earnings estimates as Crop Science sales rise, while Nubeqa and Kerendia gains help offset declines in Xarelto and Eylea.
News Placeholder
CPI Comes in Line With Expectations
CPI Comes in Line With Expectations.
News Placeholder
CPI Inflation Rate Heats Up to +3.8%
We can see clearly how disruptions in the Strait of Hormuz have affected energy prices: +3.8% overall, +5.4% for gasoline.
News Placeholder
CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch
Cytokinetics posts Q1 loss as Myqorzo launch lifts revenues to $19.4M, signaling commercial shift amid rising SG&A tied to rollout and expansion.
News Placeholder
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength
REGN tops Q1 estimates with strong Dupixent and Eylea HD growth, but the stock slips as Eylea sales plunge and competition intensifies.
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available